中国临床药学杂志

参考文献

[1]王贤才 (主译 ) .临床药物大典 .青岛 :青岛出版社 ,1994:2 48～30 0

[2 ] Torretta LK. Dexfenfluramine,fenfluramine,and phenterminefor the treatment of morbid obesity.JAm Acad Norse Pract,1997,9(8) :389

[3]肖正大 ,高玉琪 .肥胖病的药物治疗研究进展 .国外医学·内分泌学分册 ,1990 ,4:174

[4] Atkinson TL.Recent advance in the pharm acological control ofenergy balance and body weight.Ann N Y Acad Sci,1997,82 7:449

[5 ]陆德澄 ,芮涛 ,杨显祖 ,等 .吗吲哚与芬氟拉明治疗单纯性肥胖的比较 .新药与临床 ,1996 ,15 (3) :14 3

[6 ] Inoue S.Clinical studies with mazindol.Obes Res,1995 ,3(4) :5 49s

[7] Stock MJ.Sibutramine:a review of the pharmacology of novelanti-obesity agent.Int JObe Relat Metab Disord,1997,2 1(1) :2 5 s

[8] Ryan DH,Kaiser P,Bray GA.Sibutramine:a novel new agentfor obesity treatment.Obe Res,1995 ,3(4) :5 5 3s

[9] Weiser M.The pharmacologic approach to treatm ent of obesity.JClin Pharmcol,1997,37(6 ) :45 3

[10 ] Dryden S.Neuropeptide Y and energy balance:one way aheadfor the treatment of obesity?European Jof Clin Investigation,1994,2 4:2 93

[11] Finer N.Present and future pharmacological approaches. BrMed Bull,1997,5 3(2 ) :40 9

[12 ] Dulloo AG.Ephedrine,xanthines and prostaglandin-inhibitors:actions and interactions in the stimulation of thermogenesis.IntJObe Relat Metab Disord,1993,17(1) :35 s

[13] Sawynok J.Pharm acological rationale for the clinical use ofcaffeine.Drugs,1995 ,49(1) :37

[14 ] Astrup A,Breum L ,Tonbros S.Pharmacological and clinicalstudies of ephedrine and other thermogenic agonists.Obe Res,1995 ,3(4) :5 37s

[15 ] Arch JR,Wilson S.Prospects forβ3-adrenoceptor agonists inthe treatment of obesity and diabetes.Int J Obe Relat MetabDisord,1996 ,2 0 (3) :191

[16 ]高本波 ,韩启德 .β3肾上腺素受体研究进展 .中国药理学通报 ,1998,14 (1) :1

[17] Bjorntorp P.Neuroendocrine abnormalties in human obesity.Metabolism ,1995 ,44(2 ) :38s

[18] Clore JN. Dehydroepiandrosterone and body fat. Obe Res,1995 ,3(4) :6 13s

[19] Wabitsch M,Heinze E.Body fat in GH-deficient children andthe effect of treatment.Horm Res,1993,40 :5

[2 0 ] Joseph MG.Effects of growth hormone on body fat in adults.Horm Res,1993,40 :10

[2 1] Zezulak KM,Green H.The generation of insulin-like growthfactorsensitive cells by using growth hormone action.Science,1986 ,2 33:5 5 1

[2 2 ] Laron Z,Klinger B.Body fat in laron syndrome patients:effectof insulin-like growth factor I treatment.Horm Res,1993,40 :16

[2 3] Drent ML,Vander Veen EA.First clincal studies with orlistat.Obes Res,1995 ,3(4) :6 2 3s

[2 4] Thomson AB,De-Pover A,Keelan M,et al.Inhibition of lipidabsorption as an approch to the treatment of obesity.MethodsEnzymol,1997,2 86 :3

[2 5 ] Halaas JL.Weight reducing effects of the plsama proteinencoded by the obese gene.Science,1995 ,2 6 9:5 43

[2 6 ] Willian G,Haynes L.Sympathetic and cardiorenal actions ofleptin.Hypertension,1997,30 (3) :6 19

[2 7]陈霄 .肥胖基因有望作为减肥药 .国外医学·药学分册 ,1996 ,2 3(1) :46

[2 8]陈蕙芳 .治疗肥胖症的植物药 .国外药讯 ,1995 ,(1) :33

[2 9] Dvorak R,Starling RD,Escandon J,et al.Drug therapy forobesity in elderly.Drugs Aging,1997,11(5 ) :338

[30 ] Blundell JE,Halford JC.Pharmacological aspects of obesitytreatment:towards the 2 1st century.Int J Obes Relat MetabDisord,1995 ,19(3) :5 1s